Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:25:00 17/07/2026 pm IST			After hours 01:29:59 am
77.34 ^EUR	+0.52%		78.19	+1.10%

05:39pm	Sanofi strengthens its research alliance with Aqemia
04:50pm	Aqemia and Sanofi Expand Research Collaboration	CI

SANOFI : Gets a Buy rating from Deutsche Bank

Published on 06/15/2026 at 01:13 pm IST

MarketScreener with dpa-AFX Analyser

Add MarketScreener to your sources

SANOFI

+0.52%

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Buy rating. Previously set at EUR 100, the target price is lowered to EUR 95.

Add MarketScreener to your sources

Latest news about Sanofi

05:39pm	Sanofi strengthens its research alliance with Aqemia
04:50pm	Aqemia and Sanofi Expand Research Collaboration	CI
16/07	Merck gets US FDA nod for first-in-its-class oral cholesterol drug	RE
14/07	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
14/07	Where would AI lead Pharma in the long run?
14/07	AlphaValue/Baader Europe Downgrades Sanofi to Add, Trims PT	MT
13/07	SANOFI : UBS reiterates its Neutral rating	ZD
13/07	EXECUTIVE CHANGES: Rank Group confirms interim CEO Harris as permanent	AN
11/07	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
10/07	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT
10/07	The FDA Authorizes an Innovative Version of Sanofi's Sarclisa
10/07	Sanofi Says US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma	MT
10/07	US FDA approves Sanofi's wearable injector form of blood cancer drug	RE
09/07	Novo Nordisk launches weekly insulin shot Awiqli in India	RE
08/07	European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company